Related Experiment Videos
Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1
C D Liu1, A Balasubramaniam, R E Saxton
1Department of Surgery, UCLA Medical Center, USA.
Abstract:
Exogenous peptide YY (PYY) decreases pancreatic exocrine secretion, pancreatic endocrine function, and pancreatic blood flow. We hypothesized that pancreatic cancer cell growth may be inhibited by PYY and a new synthetic analog, BIM-43004-1. Two human pancreatic ductal adenocarcinomas, PANC-1 and Mia PaCa-2, were examined in tissue cultures. Viable pancreatic cancer cells were counted with trypan blue on a hemocytometer slide. Cells (10K, 20K, 40K, and 80K) were cultured and allowed to grow for 36 hr (n = 14/cell concentration). Pancreatic cancer cells received either PYY or BIM-43004-1 at various concentrations. Control tissue cultures received an equivalent volume of saline inoculation. After incubation with the above peptides for 24 hr, MTT tetrazolium bromide was added to assay mitochondrial activity of pancreatic cancer cells in response to PYY and its analog. MTT assay reveals a significant decrease in pancreatic cancer cell growth when PYY and BIM-43004-1 are added to the cell culture. Results in Mia PaCa-2 reveal a 24% cell growth reduction after exposure to PYY and a 23% reduction in cell growth when treated with BIM-43004-1. In PANC-1 cells, a 25% reduction in growth of cells is noted after PYY treatment and a 24% reduction in growth after BIM-43004-1 treatment. (means +/- SEM, P < 0.05 by Student's t test). Our results reveal a significant reduction in human ductal pancreatic cancer growth when treated with either PYY or its analog, BIM-43004-1. These agents may be useful hormonal adjuncts in the chemotherapy of pancreatic adenocarcinoma.
Insights
Peptide YY (PYY) and its analog BIM-43004-1 significantly inhibit human pancreatic cancer cell growth. These findings suggest potential new hormonal therapies for pancreatic adenocarcinoma.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Exogenous peptide YY (PYY) is known to reduce pancreatic exocrine secretion, endocrine function, and blood flow.
- Pancreatic cancer remains a significant health challenge with limited effective treatments.
Purpose of the Study:
- To investigate the inhibitory effects of peptide YY (PYY) and its synthetic analog, BIM-43004-1, on human pancreatic cancer cell growth.
- To evaluate the potential of PYY and BIM-43004-1 as therapeutic agents for pancreatic adenocarcinoma.
Main Methods:
- Human pancreatic ductal adenocarcinoma cell lines (PANC-1 and Mia PaCa-2) were cultured.
- Cells were treated with varying concentrations of PYY and BIM-43004-1.
- Cell viability and mitochondrial activity were assessed using trypan blue staining and MTT assay.
Main Results:
- Both PYY and BIM-43004-1 demonstrated a significant reduction in pancreatic cancer cell growth.
- Mia PaCa-2 cells showed a 24% growth reduction with PYY and 23% with BIM-43004-1.
- PANC-1 cells exhibited a 25% growth reduction with PYY and 24% with BIM-43004-1.
Conclusions:
- Peptide YY (PYY) and its analog BIM-43004-1 significantly inhibit the growth of human pancreatic ductal adenocarcinoma cells.
- These peptides may serve as valuable hormonal adjuncts in the chemotherapy of pancreatic cancer.
- Further research into PYY-based therapies for pancreatic cancer is warranted.